Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
76.58 USD +1.36% Intraday chart for Intra-Cellular Therapies, Inc. +13.00% +6.93%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Needham Adjusts Intra-Cellular Therapies Price Target to $94 From $90, Maintains Buy Rating MT
RBC Capital Adjusts Intra-Cellular Therapies Price Target to $103 From $96, Maintains Outperform Rating MT
Goldman Sachs Adjusts Intra-Cellular Therapies Price Target to $77 From $76, Maintains Neutral Rating MT
Mizuho Securities Adjusts Intra-Cellular Therapies Price Target to $100 From $96, Maintains Buy Rating MT
Canaccord Genuity Adjusts Intra-Cellular Therapies Price Target to $113 From $107, Maintains Buy Rating MT
Intra-Cellular Therapies Says Depressive Disorder Therapy Meets Primary, Secondary Endpoints in Second Late-Stage Study MT
Transcript : Intra-Cellular Therapies, Inc. - Special Call
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder CI
Certain Common stock of Intra-Cellular Therapies, Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2024. CI
Certain Restricted Stock Units of Intra-Cellular Therapies, Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2024. CI
Certain Stock Options of Intra-Cellular Therapies, Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2024. CI
Transcript : Intra-Cellular Therapies, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM
Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024
Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises MT
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M MT
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M MT
Intra-Cellular Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating MT
Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating MT
Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating MT
Intra-Cellular Therapies Prices $500 Million Stock Offering MT
Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating MT
Chart Intra-Cellular Therapies, Inc.
More charts
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
76.58 USD
Average target price
92.22 USD
Spread / Average Target
+20.43%
Consensus
  1. Stock Market
  2. Equities
  3. ITCI Stock
  4. News Intra-Cellular Therapies, Inc.
  5. Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises